NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
Search Results
14 Results
The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community.
The core services team provides cell culture, hematology, hemostasis, clinical chemistry, microbiology, and molecular virology support for infectious disease studies at the IRF-Frederick. The team has the ability to perform pre-screening assessment by having parallel setups of clinical analyzers in biosafety level 4 (BSL-4) and BSL-2.
The drug screening team tests and characterizes novel compounds, drugs, and antibodies against numerous viruses in multiple cell lines under a variety of conditions. Compounds are evaluated in cell-based assays for inhibition of viral replication and reduction of virus yields, plaques, or cytopathic effect.
The electron microscopy (EM) laboratory team uses transmission electron microscopy (TEM), scanning electron microscopy (SEM), negative staining techniques and assays, immunogold labeling, quantitation of biological samples, and other specialized methods.
The Filariasis Research Reagent Resource Center (FR3) maintains oversight of filarial parasites, SOPs, and molecular reagents. FR3 is comprised of two divisions: The Parasite Resource Division and the Molecular Resources Division.
The immunology team interrogates immune responses against pathogens requiring maximum containment by use of a variety of capabilities.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo and complex human cell-based in vitro model preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Schistosomiasis Resource Center (SRC) provides three major strains of snails (Biomphalaria glabrata, Bulinus truncatus, and Oncomelania hupensis) and rodents infected with S. haematobium, S.
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.
Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.
The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).